Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODOXY vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Management of moderate to moderately severe pain where the use of an opioid analgesic is appropriate
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Terminal half-life is 3.5 hours in patients with normal renal function; extends to 5-8 hours in moderate renal impairment.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Oxycodone is metabolized by CYP3A4 and CYP2D6. N-demethylation to noroxycodone (via CYP3A4) is the primary metabolic pathway. CYP2D6-mediated O-demethylation to oxymorphone is a minor pathway but produces a more potent metabolite.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; biliary/fecal excretion accounts for 30%.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Approximately 92% bound to albumin.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
2.4 L/kg; indicates extensive tissue distribution.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Oral: 60-70% due to first-pass metabolism.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
For GFR 30-50 m L/min: administer every 8 hours. For GFR 10-29 m L/min: administer every 12 hours. For GFR <10 m L/min: use not recommended.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and extend interval to every 8 hours. Child-Pugh Class C: contraindicated.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
For children ≥2 years: 0.1-0.2 mg/kg hydrocodone component every 4-6 hours as needed, maximum 6 doses per day. Use weight-based dosing; do not exceed acetaminophen 75 mg/kg/day.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Initiate at lowest effective dose (e.g., 1 capsule every 6 hours) due to increased risk of respiratory depression and falls. Titrate cautiously. Maximum 6 capsules per day.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome; adrenal insufficiency; and androgen deficiency.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oxycodone, aspirin, or any component of the formulation.
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Avoid alcohol and grapefruit juice. Alcohol potentiates CNS depression. Grapefruit juice may increase codeine metabolism via CYP3A4, leading to variable effects. No significant food restrictions otherwise; take with food if GI upset occurs.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Oxycodone is excreted into breast milk; M/P ratio ~3.6:1. Risk of infant sedation and respiratory depression. Contraindicated during breastfeeding.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
No established dose adjustments; increased clearance in pregnancy may require higher doses for analgesia, but use is contraindicated.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
CODOXY is a fixed-dose combination of codeine (opioid) and doxylamine (antihistamine). Use lowest effective dose for shortest duration due to opioid dependence and respiratory depression risk. Avoid in children <12 years for post-tonsillectomy pain and in those <18 with respiratory compromise. Monitor for CNS depression, especially with alcohol. Doxylamine adds anticholinergic effects (constipation, dry mouth, urinary retention). Caution in elderly, renal impairment, and breastfeeding.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other sedatives (e.g., benzodiazepines, sleep aids) as they increase risk of severe drowsiness and breathing problems.,Do not use with other products containing codeine or antihistamines (including cough/cold medicines).,Store securely away from children; misuse can cause addiction, overdose, or death.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your healthcare provider before use.,Common side effects: constipation, dry mouth, nausea. Increase fluid intake and fiber to prevent constipation.,Seek emergency help if you experience slow or shallow breathing, confusion, or fainting.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
No interactions on record
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODOXY vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
CODOXY is a Antitussive Combination that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODOXY and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODOXY is: 1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODOXY and ACETAMINOPHEN AND IBUPROFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODOXY is classified as Category C. No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.